What is the current status and use of Bimagrumab in treating medical conditions such as muscular dystrophy or sarcopenia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 23, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Bimagrumab is not currently approved for clinical use in treating muscular dystrophy or sarcopenia, and its development for these conditions has been largely discontinued due to insufficient efficacy in phase II and III trials. This monoclonal antibody works by blocking activin type II receptors, which inhibit muscle growth, theoretically allowing for increased muscle mass development. In clinical trials, bimagrumab has demonstrated some ability to increase muscle mass in patients with inclusion body myositis and sarcopenia, but these benefits have not consistently translated to meaningful functional improvements in muscle strength or mobility 1. The drug has also been investigated for potential use in treating cachexia associated with cancer and other chronic diseases. While some studies have shown positive effects on body composition, including increased lean mass and reduced fat mass, research continues to explore its potential in metabolic conditions like type 2 diabetes and obesity, where its effects on body composition might prove beneficial 2.

Key Findings

  • Bimagrumab has been shown to increase lean body mass and reduce fat body mass in clinical trials 2, 3
  • The drug has a target-mediated drug disposition profile, with a subcutaneous bioavailability of approximately 40% 4
  • Bimagrumab is generally safe and well-tolerated, with mostly mild to moderate adverse events 4
  • The development program for muscular disorders has been largely discontinued due to insufficient efficacy in phase II and III trials

Clinical Use

  • Patients interested in treatments for muscle-wasting conditions should consult with specialists about currently approved therapies and clinical trials, as bimagrumab remains an experimental agent not available for routine clinical use
  • Research continues to explore the potential of bimagrumab in metabolic conditions like type 2 diabetes and obesity, where its effects on body composition might prove beneficial 2

Future Directions

  • Further studies are needed to fully understand the potential benefits and risks of bimagrumab in various clinical contexts
  • The feasibility of subcutaneous administration of bimagrumab supports its potential for future clinical development 4

References

Related Questions

What is the current status of Bimagrumab (anti-myostatin monoclonal antibody) for treating medical conditions like muscular dystrophy or sarcopenia?
What is the treatment for colitis with a contained perforation?
What is seen on lateral decubitus (decubitus position, where the patient lies on their side) films in cases of suspected aspiration?
What ECG (electrocardiogram) findings can be misleading or absent in a myocardial infarction (MI), especially in posterior or right ventricular infarctions?
What are the clinical suspicions and initial management steps for a suspected posterior myocardial infarction (MI)?
What are the best evidence-based treatments for facial rejuvenation?
Should a patient with colitis and a contained perforation be admitted to a hospital medicine service or a surgery service?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question